Patient P-02524
Synthetic patientMETA-24 · Day 172 · 45–54 · M · baseline S07Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Deteriorating
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Declining
Discontinuation risk
26%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S07
- Day 26 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 26.
Primary contributors, last 14 days
- Nutritional resilience-9
- Toxicity+5
- Treatment adherence+3
What helped?
No interventions yet.
LIFE OS recommendation
Dietary Support Protocol NP-02
40%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 50% showed improvement
- median effect visible after 10 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable72 min
stable · -2.2 vs previous 14 d
Sleep duration
Wearable5.9 h
stable · -0.1 vs previous 14 d
Energy level
Daily log3.9/10
worsening · -0.2 vs previous 14 d
Steps
Wearable8,738
worsening · -512 vs previous 14 d
GI burden
Companion32/100
worsening · +10.1 vs previous 14 d
Adherence
Companion92.6 %
stable · +0.4 vs previous 14 d
Sleep quality
Wearable37.7/100
worsening · -2.3 vs previous 14 d
Glucose, CGM daily mean
CGM143 mg/dL
stable · +4.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 57 from the failing basin, 31 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4.5 next day on high-intake days · n 21
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.5supporter · 95%
- Alcohol+1no signal · 25%
- Ultra-processed food-0.7no signal · 17%
- Histamine load+0.5no signal · 15%
- Insoluble fibre+0.5no signal · 15%
- Simple carbohydrates-0.4no signal · 15%
- Dietary fat load-0.1no signal · 15%
- Caffeine+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
- Autonomic recovery ↑20
- WearableShort sleep window
- Mucosal barrier integrity ↓10
- WearableSleep 5.9 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 3 · butyrate capacity 46/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 55 ms
- Sleep
- 5.7 h
- Steps
- 8,706
- Resting HR
- 69 bpm
Daily log: GI score 32, nutritional resilience 52, adherence 93.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02462 | 41% | S12 | DT-01 | improved | 65 |
| P-02459 | 40% | S05 | HY-01 | improved | 52 |
| P-02298 | 39% | S14 | GI-04 | improved | 65 |
| P-02082 | 38% | S12 | NP-02 | improved | 53 |
| P-02538 | 38% | S02 | GI-04 | improved | 59 |
| P-02339 | 37% | S03 | DT-01 | improved | 50 |
| P-02395 | 37% | S12 | DT-01 | improved | 57 |
| P-02685 | 37% | S16 | DT-01 | improved | 47 |
| P-02274 | 36% | S15 | DT-01 | improved | 50 |
| P-02620 | 36% | S01 | HY-01 | improved | 64 |
| P-02223 | 35% | S20 | HY-01 | improved | 49 |
| P-02235 | 35% | S14 | DT-01 | improved | 50 |